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Abstract
Persistent immune activation plays a central role in driving Human Immunodeficiency Virus (HIV) disease progression.
Whether CD4+CD25+ regulatory T cells (Tregs) are harmful by suppressing HIV-specific immune responses and/or beneficial
through a decrease in immune activation remains debatable. We analysed the relationship between proportion and number
of regulatory T cells (Tregs) and immune activation in HIV-infected patients interrupting an effective antiretroviral therapy
(ART). Twenty-five patients were included in a substudy of a prospective multicenter trial of treatment interruption (TI)
(ANRS 116). Proportions and numbers of Tregs and the proportion of activated CD4 and CD8 T cells were assessed at
baseline and month 12 (M12) of TI. Specific anti-HIV CD4 and CD8 responses were investigated at baseline and M12. Non
parametric univariate analyses and multivariate linear regression models were conducted. At baseline, the proportion of
Tregs negatively correlated with the proportion of HLA-DR
+CD8
+T cells (r=20.519). Following TI, the proportion of Tregs
increased from 6.3% to 7.2% (p=0.029); absolute numbers of Tregs decreased. The increase in the proportion of HLA-
DR
+CD38
+CD8
+T cells was significantly related to the increase in proportion of Tregs (p=0.031). At M12, the proportion of
Tregs did not negatively correlate with CD8 T-cell activation. Nevertheless, Tregs retain a suppressive function since
depletion of Treg-containing CD4
+CD25
+ cells led to an increase in lymphoproliferative responses in most patients studied.
Our data suggest that Tregs are efficient in controlling residual immune activation in patients with ART-mediated viral
suppression. However, the insufficient increase in the proportion and/or the decrease in the absolute number of Tregs result
in a failure to control immune activation following TI.
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Introduction
HIV infection is associated with a progressive depletion of CD4
+
T lymphocytes and defective HIV specific T-cell responses.
Persistent immune activation plays a central role in driving CD4
T cell depletion and progression to AIDS [1,2,3].
Regulatory T cells (Tregs) may influence the outcome of various
infections [4]. CD4
+CD25
+Treg cells are able to suppress antigen-
specific T-cell responses against a variety of pathogens and also to
control inappropriate or exaggerated immune activation induced
by various pathogens, thus limiting immune-mediated tissue
damage [5,6,7]. In HIV/SIV infection, Tregs, capable of
suppressing HIV/SIV-specific immune responses, are detected
in peripheral blood and lymphoid tissues and may contribute to
immune suppression [8,9,10,11,12,13]. Whether these cells are
harmful by suppressing HIV-specific immune responses or
beneficial through a decrease in immune activation remains
debatable. Conflicting data have been reported regarding the
relationship between Treg activity, immune activation and HIV/
SIV disease progression. The level of Tregs has been found to be
unaffected, expanded or decreased with disease progression
[9,14,15,16,17,18]. Similarly, results regarding the ability of Tregs
to control chronic immune activation associated with HIV/SIV
infection were not consistent among studies [19,20,21,22,23].
These discrepancies may result from a disparity in the markers
used to identify Tregs, the compartments studied (i.e. peripheral
blood vs lymphoid tissues) and the stage of the disease. Tregs have
been shown to display low surface expression of CD127,
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CD4
+CD25
+CD127
low/2T cells exhibit higher levels of intracel-
lular FOXP3 and CTLA-4 and are suppressive in functional
assays [27]. In addition, Lim et al [22] recently validated the use of
CD4+CD25
+CD127
low/2 as a phenotypic marker of CD4 Treg
cells in antiretroviral naı ¨ve HIV-infected patients.
To date, the effects of viral rebounds on the proportion, number
and function of Tregs in patients interrupting combination
antiretroviral therapy (cART) are unknown. The level of immune
activation following cART discontinuation may hamper the
discrimination between activated and Treg cells. We postulated
that, following cART interruption, CD4
+CD25
+Treg cells might
be expanded in the periphery as a consequence of repeated
antigen exposure and/or immune activation. We asked the
question whether expanded regulatory T cells might be able to
control immune activation and therefore influence the immuno-
virologic outcome after cART interruption. The aim of the study
was to analyse the relationship between the proportion and
number of Tregs (defined here according to expression of both
CD25 and CD127) and immune activation in patients interrupting
an effective antiretroviral regimen.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1."
Patients - Study design
The ANRS 116 trial was a prospective, open-label, multicentre
trial of ART interruption in patients who had started treatment
early (ClinicalTrials.gov Identifier, NCT00118677). The results of
this non randomized trial are described elsewhere in the main
publication of the study [47]. Briefly, inclusion criteria were as
follows: patients treated at CD4 cell count .350/mL and plasma
viral load (VL),50,000 copies/ml, receiving stable ART within 6
months prior to inclusion with no more than one prior treatment
failure and exhibiting, at baseline, CD4 cell count .450/mL and
stable VL ,5000 copies/mL. All patients provided written
informed consent; the study was approved by the ethical
committee of Ho ˆpital Pitie ´-Salpe ´trie `re, Paris, France. Antiretro-
virals were interrupted at Day 0 (Baseline). Criteria to resume
ART were a decrease in CD4 cell count to below 300/mL or the
occurrence of a stage B or C event [28]. Patient disposition during
the ANRS 116 trial is presented in Flowchart S1.
The Tregs’study was proposed to all patients from the Paris area
sites. Peripheral blood mononuclear cells (PBMCs), were collected
at baseline (before TI) and after 12 months of TI (M12). PBMCs
were used immediately for proliferation assays and cryopreserved
for phenotypic studies and ELISpot assays.
An immunological substudy was systematically proposed to
patients enrolled in the main study in centers from Paris area.
Twenty-five patients (18 men and 7 women) were enrolled in the
substudy. Twelve patients were receiving a non-nucleoside reverse
transcriptase inhibitor-based regimen; 3 patients a protease
inhibitor-based regimen; 8 patients a triple nucleoside analogue
therapy while 2 patients received a dual nucleoside analogue
therapy.
Flow Cytometric Analysis
The following antibodies were used: anti-CD4 conjugated to
phycoerythrin(PE)-Cy7 or Texas Red-PE (ECD), anti-CD8 PC5,
anti-CD127 conjugated to fluorescein isothiocyanate (FITC), anti-
CD25 PE, anti-CD3 conjugated to allophycocyanin (APC), anti-
HLA-DR FITC, anti-CD38 PE (Beckman Coulter). Cells from
healthy controls were used in all staining experiments. Analyses
were performed using FC500 flow cytometer and CXP software
(Beckman Coulter) on at least 1000 gated events.
Proliferation and suppressive assays
As previously described [8], freshly-obtained PBMCs were
assessed for proliferative capacities following stimulation with
HIV-p24 protein (Protein Science Corp.), purified tuberculin
(PPD, Statens Serum Institute) and cytomegalovirus (CMV)
antigen (Bio Whittaker). Stimulation indexes were calculated by
dividing the mean cpm of stimulated cells by the mean cpm of
unstimulated cells. A stimulation index $3 and $3000 cpm
incorporated was considered as a positive response.
We tested the suppressive activity of CD4
+CD25
+Tregs in 10
patients for whom fresh samples were available at M12 of TI.
Purified CD4+ T lymphocytes (RosetteSep
TM CD4+ enrichment
antibody cocktail, StemCell Technologies) were incubated with
CD25
+ magnetic beads (Myltenyi Biotec) for 30 min at 4uC. The
CD25
2 fraction (.90% purity) was collected. Unfractionated
CD4
+ cells and CD4
+CD25
2 cells cultured in the presence of
1610
4 autologous monocytes were assessed for proliferative
capacities.
ELISpot assays
ELISpot assays were performed as previously described [29]. A
set of 18 pools of 15-mer synthetic HIV peptides covering Gag,
Reverse Transcriptase and Nef regions, synthesized by Neosystem
and kindly supplied by the ANRS was used. Briefly, 96-well
polyvinylidene difluoride plates (Millipore, Molsheim, France)
were coated with capture antihuman IFN-c mAb at 1 mg/ml
(Diaclone, Besanc ¸on, France). PBMC were added in triplicate
wells at 1610
5 cells per well in the presence of pools of HIV
peptides (final concentration of 2 mg/ml) or the combination of
phorbol 12-myristate 13-acetate, PMA: 100 ng/mL) (Sigma, St
Louis,MO) and ionomycin (10 mM) (Sigma) as positive controls or
in the presence of culture medium as negative controls. After 20 h
incubation and washing, the second biotinylated mouse anti-IFN-c
monoclonal antibody (Diaclone) was added, followed by strepta-
vidin-alkaline phosphatase conjugate (Diaclone) and chromogen
substrate (nitroblue tetrazolium/5-bromo-4-chloro-3-indolylpho-
sphate toluidinemix from Diaclone). Frequencies of antigen-
specific spot-forming cells (SFC) were measured with an
automated microscope (Zeiss).Results were expressed as SFC per
million PBMC and were calculated for each pool of peptides as
follows: 106 (mean SFC/10
5 cells from three antigen-stimulated
wells - mean SFC/10
5 cells from unstimulated wells).
Virological assays
Plasma HIV-RNA levels were determined in each study site,
using the locally available technique with a lower limit of detection
of 400 copies/mL. HIV-DNA levels in PBMCs were measured by
real time PCR, as described elsewhere [30]. Final results were
expressed as the log10 number of HIV-1 DNA copies per 10
6
PBMCs (threshold: 60 copies/10
6 PBMCs).
Statistical analyses
Non parametric tests were used to avoid the impact of potential
outlier values in a small study. The changes between baseline and
M12 after TI were compared using paired Wilcoxon test for
continuous variables and McNemar test for categorical variables.
The association between markers of interest at baseline, at M12,
association between markers at baseline and the change between
Immune Activation-Tregs in HIV
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correlation to study association of two continuous variables and
Mann-Whitney test to study association of one continuous variable
and one categorical variable. Multivariable linear regressions were
used to assess the factors independently associated with the
proportion of Tregs at baseline and the change in the proportion
of Tregs including variables with p-value ,0.20 in the univariate
analyses. For the HIV-RNA levels at M12, the change in HIV-
DNA and the change in CD4 count between baseline and M12,
we systematically assessed, in multivariable linear regressions, the
role of baseline values of CD4 counts, HIV-DNA levels, CD4 and
CD8 T-cell activation and the baseline proportion of Tregs. A
backward elimination technique was used to determine the
independent factors associated with each endpoint, limiting the
number of variables left in the model because of the small study.
All reported p values are two-tailed, with a significance level of
0.05. We used FDR method to account for multiplicity issue and
we used corrected p value from SAS 9.1. We have also checked
linear model assumptions before their used. Analyses were
performed with the SPSS software package version 15.0 for
Windows (SPSS Inc.) and with the SAS software package version
9.1 for Windows (Cary NC, USA).
Results
Study population
The patients’ characteristics are depicted in Table 1. The
patients did not differ from the overall study population in terms of
age, sex, CD4 counts, HIV-RNA and HIV-DNA levels. All
patients had plasma HIV-RNA levels ,400 copies at baseline. In
patients with cART-mediated suppression, HIV-DNA level in
PBMCs was the unique virologic marker available. None of the 25
patients had resumed cART at M12.
At baseline, HIV-DNA levels in PBMCs negatively correlated
with CD4 T-cell counts (n=25, r=20.430; p=0.039), anti-HIV-
CD8 T-cell responses (n=22, r=20.502; p=0.026) and anti-p24
CD4 T-cell proliferation (n=22, r=20.425; p=0.055).
At M12 of TI, HIV-RNA and HIV-DNA levels strongly
correlated (n=25, r=0.852; p,0.001). CD4 cell counts negatively
correlated with viral load (n=25, r=20.572; p=0.009 for plasma
HIV-RNA levels and r=20.421; p=0.042 for HIV-DNA levels).
As expected [31], specific anti-HIV CD8 T-cell responses were
amplified and broadened. Among the 22 patients with available
data for anti-HIV-p24 lymphoproliferative CD4 responses at
baseline and month 12, the proportion of responses decreased
from 27% to 4%.
In patients with cART-mediated viral suppression, the
proportion of regulatory T cells negatively correlated
with the proportion of CD8
+ T cells expressing HLA-DR
At baseline, a median of 6.3% of CD4
+ T cells expressed the
CD25
+CD127
2/low phenotype, defined here as Tregs. To
investigate the role of Tregs in controlling immune activation in
vivo, we sought a relationship between the proportion and/or the
numbers of Tregs and the level of T-cell activation. CD4 and CD8
T-cell activation were linked since the proportion of CD8
+ T cells
HLA-DR
+ positively correlated with the proportion of CD4
+ T
cells HLA-DR
+ (n=25, r=0.525; p=0.014). As illustrated in
Fig. 1a, the proportion of Tregs at baseline negatively correlated
with the percentage of activated HLA-DR
+ CD8
+T cells (n=25,
r=20.519; p=0.015). Interestingly, the proportion of Tregs
positively correlated with HIV-DNA in PBMCs (n=25, r=0.553;
p=0.010) and negatively correlated with anti-HIV CD8 T-cell
responses (n=22, r=20.461; p=0.039).
In the multivariable analysis, only the proportion of CD8
+T
cells expressing HLA-DR was found to be independently
associated with the proportion of Tregs at baseline (n=22,
b=20.65460.225, p=0.009and b=22.18760.878, p=0.022,
respectively).
Following cART interruption, the proportion of Tregs
increased as a result of immune activation
After 12 months of TI, the proportion of Tregs among CD4
+ T
cells increased from 6.3% to 7.2% (n=25, p=0.038). In contrast,
absolute numbers of Treg cells decreased according to the drop of
CD4 T-cell counts (Table 1, Fig. 2).
Both, the proportion of Tregs and the proportion of CD4
+ and
CD8
+T cells expressing CD38 positively correlated with plasma
HIV-RNA levels at M12 of TI (n=25, r=0.470; p=0.026 for
Tregs and r=0.750; p,0.001 and r=0.555; p=0.010 for CD4
and CD8 T-cell activation, respectively). We did not find any
relationship between the absolute numbers of Tregs and the level
of CD4 or CD8 T-cell activation.
We looked for the factor(s) that influence Treg evolution
between baseline and M12 of TI in multivariable analyses, and
found that the only factor independently related to the increase in
Tregs’proportion following TI was the increase in the proportion
of CD8
+T cells co-expressing HLA-DR and CD38 (n=25,
b=3.34561.025, p=0.005) (Fig. 3).
In patients with viral replication following TI, the
proportion of Tregs did not negatively correlate with the
level of CD8 T-cell activation
Interestingly, contrary to baseline, we no longer found, at M12
of TI, a negative correlation between the proportion of
CD25
+CD127
2/lowTregs and the percentage of CD8
+T cells
expressing HLA-DR (Fig. 1b). We even found a positive
relationship between the proportion of Tregs and the proportion
of CD8
+ T cells and CD4
+ T cells expressing CD38 (n=25,
r=0.539; p=0.010 and r=0.616; p=0.004, respectively). These
data suggest that, following TI, Tregs are no longer capable of
controlling immune activation resulting from viral replication.
Tregs retain a suppressive activity in patients undergoing
cART Interruption
In order to assess if the Tregs detected after TI retain a
suppressive activity, we compared the proliferative capacity of total
CD4
+T cells and of CD4
+T cells depleted of CD4
+CD25
+T cells
in a subgroup of 10 patients for whom fresh PBMC were available.
Depletion of Tregs-containing CD4
+CD25
+cells led to an increase
($2-fold) in lymphoproliferative responses (LPR) to HIV-p24 and
to CMV antigen in 4/10 patients and 5/10 patients, respectively.
Altogether, depletion of Tregs-containing CD4
+CD25
+cells led to
an increase of LPR to at least one antigen (HIV-p24, CMV or
PPD) in 7/10 patients, indicating that CD4
+CD25
+T cells from
patients who stopped ART retain a suppressive activity.
Treg cells at baseline did not affect the immunovirologic
outcome at 12 months of cART interruption
We then investigated whether the proportion and/or the
numbers of CD25
+CD127
2/lowTregs at baseline may indepen-
dently influence the extent of the CD4 cell decline and the degree
of virologic rebound. In addition, we sought other immunologic
and virologic parameters at baseline that may independently
predict the CD4 T-cell drop and the increase in viral load
following TI.
Immune Activation-Tregs in HIV
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N=25 Median (IQR
$) P value* M12 vs BL
Gender (male), n (%) 18 (72%)
Age (years), median (IQR) 41 (37–47)
Transmission group, n (%) Homo/bisexual men 14 (56%)
Heterosexuals 8 (32%)
Intravenous drug users 2 (8%)
Duration of cART (years), median (IQR) 5 (3–6)
CD4 cells count (cells/mm
3), median (IQR)
Baseline** 816 (624–892) P,0.001, n=25
Month 12 497 (381–618)
Plasma HIV-RNA (log10 copies/mL), median (IQR),
Baseline** ,2.6 P,0.001, n=25
Month 12 4.25 (3.69–4.57)
HIV DNA (log10 copies/10
6 PBMCs), median (IQR)
Baseline** 2.56 (2.00–2.93) P,0.001, n=25
Month 12 3.13 (2.67–3.49)
%CD4+CD25+CD1272/low/CD4+
Baseline** 6.3 (4.4–7.8) P=0.038, n=25
Month 12 7.2 (4.7–10.8)
Absolute values CD4+CD25+CD1272/low (/mL)
Baseline** 41.9 (33.1–61.2) P=0.010, n=25
Month 12 36.4 (26.1–46.3)
% HLA-DR+CD38+/CD8+ T cells
Baseline** 0.4 (0.2–0.6) P=0.019, n=25
Month 12 0.5 (0.2–1.7)
% CD38+/CD8+ T cells
Baseline** 8.8 (5.8–11.1) P=0.004, n=25
Month 12 11.9 (7.7–17.3)
% HLA-DR+/CD8+ T cells
Baseline** 3.2 (1.7–5.0) P=0.904, n=25
Month 12 3.6 (1.5–5.4)
%CD38+/CD4+
Baseline** 10.5 (8.9–17.1) P,0.001, n=25
Month 12 23.6 (18.2–32.3)
%HLA-DR+/CD4+
Baseline** 3.4 (2.0–4.4) P=0.794, n=25
Month 12 2.6 (1.8–4.6)
Anti-HIV CD8 T-cell responses
Total SFC/10
6 PBMC to HIV pools, n=21
Baseline** 485 (154–1397) P=0.006, n=21
Month 12 2598 (1053–3810)
Number of positive HIV pools, n=21
Baseline** 2 (1–5) P=0.023, n=21
Month 12 4 (3–7)
Anti-HIV CD4 T-cell responses
p24-LPR, % responders, n=22 Baseline** 6 (27.3%) P=0.068, n=22
Month 12 1 (4.5%)
$IQR: Interquartile Range.
*Paired Wilcoxon test for continuous variables and Mc Nemar test for categorical variables.
**Baseline (BL) = before treatment interruption.
doi:10.1371/journal.pone.0011659.t001
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number of Tregs at baseline and the immunovirologic outcome at
M12. Equally, we did not find any impact of HIV-specific CD4
and CD8 T-cell responses before TI on the immunological and
virologic status achieved at M12 of TI.
The factors that independently predicted the CD4 T-cell decline
between baseline and M12 were the CD4 T-cell count and the
HIV-DNA levels in PBMCs at the time of TI (n=25, b=279616,
p,0.001 and b=2127641, p=0.006, respectively). The decline
of CD4 T-cell count was found to be more substantial whenever
HIV-DNA levels or CD4 T-cell counts were high. Fig. 4 illustrates
the relationship between baseline HIV-DNA levels and the extent
of CD4 cell decline between baseline and M12.
The increase in HIV-DNA between baseline and M12 was
independently predicted by the number of CD4
+ T cells and the
proportion of CD8
+ T cells co-expressing CD38 and HLA-DR at
baseline (n=25, b=0.09860.034; p=0.008 and b=0.2316
0.073; p=0.004, respectively). The increase in HIV-DNA level
was more important when CD4 T-cell counts and immune
activation were high. The relationship between the proportion
of CD8
+ cells co-expressing HLA-DR and CD38 and the increase
in HIV-DNA levels between baseline and M12 is shown in
Fig. 5.
Finally, the HIV-DNA level in PBMCs and the proportion of
activated CD38
+HLA-DR
+CD8
+ T cells before TI were indepen-
dent predictors of the level of plasma HIV-RNA achieved at M12
(n=25, b=0.79060.100; p,0.001 and b=0.17260.082;
p=0.048, respectively).
Discussion
Data from the present study strongly suggest that regulatory T
cells are capable of controlling residual immune activation in
patients under cART but not the immune activation resulting
from viral replication after cART interruption.
Patients included in the present study were treated early in the
course of HIV infection and exhibited, at baseline under cART,
high CD4 cell counts, undetectable plasma HIV-RNA and
relatively low levels of HIV-DNA in PBMCs [30]. At baseline
we found an inverse relationship between HIV-DNA levels and
CD4 T-cell counts. The level of HIV-DNA has been reported to
be a major and independent predictor of disease progression in
untreated patients with primary HIV infection [30,32,33]. It has
been suggested that the level of HIV-DNA in PBMCs reflects the
number of circulating HIV-infected cells representing the cellular
stock.
Despite the limited size of the patient population and the fact
that we only studied the blood compartment, our study is
important since we had the opportunity to investigate Tregs when
viral replication starts again after a long period of viral control
under effective cART.
As expected, following TI plasma HIV-RNA and HIV-DNA
levels in PBMCs increased while CD4 cell counts decreased and
circulating CD4 and CD8 T cells became activated. Thus, the
proportion of CD4
+ and CD8
+ T cells expressing CD38 was found
to significantly increase unlike T cells expressing HLA-DR. We
found, in our study, a relatively low proportion of HLA-DR
+ T
cells because we considered, as positive cells, only T cells which
expressed high levels of HLA-DR. Nevertheless, some discrepan-
cies between the expression of HLA-DR and CD38 markers on
activated T cells have already been reported. HLA-DR expression
was found to correlate with Ki-67 expression and but not
consistently with viral load in HIV-infected patients [34,35].
Thus, HLA-DR
+ CD38
2 T cells probably represent proliferating
cells whereas CD38
+ T cells preferentially increase as a result of
viral replication [36]. Finally, none of the available cellular
markers of T-cell activation or proliferation appears to be able
alone to consistently and robustly assess the level of immune
activation across all subsets of HIV-infected patients [37]. Thus,
we chose to evaluate immune activation by the proportion of CD4
and CD8 T cells expressing HLA-DR or CD38 or co-expressing
both markers.
At baseline, the inverse relationship between the proportion of
CD4
+CD25
+CD127
2/lowTregs and the proportion of activated
HLA-DR
+CD8
+T cells strongly suggests that in vivo, in patients
with cART-mediated viral suppression, Tregs are capable of
controlling residual immune activation. However, as we did not
find a negative relationship between the proportion of CD8 T cells
expressing CD38 and the proportion of Tregs, it cannot be
excluded that Tregs control spontaneous T-cell proliferation
rather than generalized immune activation in this context. The
recent report of a preservation of Tregs in peripheral blood of elite
suppressors also suggests that Tregs are beneficial rather than
damaging in HIV-infected patients controlling HIV replication
[23]. However, the inverse relationship between the proportion of
peripheral Tregs and specific anti-HIV CD8 T-cell responses that
we found, indicated that, as demonstrated in vitro [9,10,38], Tregs
can suppress HIV-specific CD8 T-cell responses in vivo. The
positive relationship between HIV-DNA levels and the proportion
Figure 1. The proportion of Tregs negatively correlated with
CD8 T-cell activation at baseline but not at 12 months of
treatment interruption (TI). Panel A: Relationship between the
percentages of CD8+ T cells expressing HLA-DR (x-axis) and the
proportion of CD25+ CD1272/low Tregs among CD4+ T cells at
baseline prior to TI (y-axis). Spearman’s correlation coefficient
R=20.519, p=0.008 Panel B: Relationship between the percentages
of CD8+ T cells expressing HLA-DR and the proportion of CD25+
CD1272/low Tregs among CD4+ T cells after 12 months of TI (y-axis).
Spearman’s correlation coefficient R=0.129; p=0.539.
doi:10.1371/journal.pone.0011659.g001
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HIV, as suggested by previous reports of HIV-specific Tregs in
patients with chronic or primary infection [8,39] and/or indirectly
by immune activation resulting from HIV replication.
To gain insight into the role of Tregs in vivo, we further
analysed Treg evolution following cART interruption. We
found, in the multivariable analysis, that the increase in the
proportion of Tregs between baseline and M12, although quite
modest, was only independently related to the level of
generalized immune activation (i.e. the proportion of CD8
+T
cells co-expressing CD38 and HLA-DR). This indicated that the
proportion of Tregs among CD4
+ T cells expanded as a result of
immune activation. Viral replication and immune activation
following TI increase interactions between HIV or envelope
proteins and CD4 or HIV-co-receptors, and may favor the
peripheral conversion of memory activated CD4 T cells into
Treg [40]. In agreement with recent results [23], we found no
evidence for a preferential depletion of Tregs in viremic patients
off-treatment.
CD4 and CD8 T-cell activation at M12 of TI positively
correlated with plasma VL suggesting that, in patients interrupting
cART, immune activation is primarily driven by HIV. Interest-
ingly, we did not observe after M12 of TI an inverse relationship
between the proportion of Tregs and the proportion of CD8
+T
cells expressing HLA-DR and/or CD38. We found a positive
relationship between the proportion of Tregs and the proportion
of CD4
+ T cells expressing CD38 suggesting that, as previously
suggested in viremic patients [41], CD4
+CD25
+CD127
lo may
include activated CD4
+ T cells and/or that CD4 T cell activation
drives Treg expansion. The lack of inverse relationship between
the proportion of Tregs and CD8 T-cell activation following TI
strongly suggests that, in the situation of viral replication and
subsequently increased immune activation, Tregs are no longer
capable of regulating T-cell activation in most patients, as recently
described in ART-naive patients [22]. The ability of Tregs to
control immune activation in vivo thus may vary according to the
level of T-cell activation needed to be contained; this may explain
conflicting results previously reported. Thus, in very early stage of
Figure 2. Proportion and absolute numbers of CD4+CD25+CD1272/low Tregs at baseline prior to treatment interruption (TI) and
after 12 months off-treatment. The expression of CD25 and CD127 was determined on thawed cryopreserved PBMC by 5-color flow cytometry
after successively combining the FSC/SSC, CD3+ and CD4+ gates. Regulatory T cells were defined as CD25+ and CD1272/low.Results are expressed as
percentages (panel A) and absolute numbers (panel B) of CD25+ CD1272/low Tregs among CD4+ T cells at baseline and after 12 months of TI
(n=25). The band near the middle of the box indicates the median, the bottom and the top of the boxes are the 25th and 75th percentile. Asterisks
indicate a significant difference between M12 and baseline values. Representative stainings of PBMC from one patient at baseline (panel C) and at 12
months of TI (panel D) are shown.
doi:10.1371/journal.pone.0011659.g002
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is low despite high viral load, Tregs might be able to control
immune activation [20].
The inefficiency of Tregs to control immune activation in the
context of TI may result from the decrease in the absolute
numbers of Tregs and/or an insufficient increase in the proportion
of Tregs or from a defect in Treg suppressive function. Finally,
Tregs could have migrated to lymphoid tissues, as suggested by
previous studies in humans and macaques [17,18,42]. We
previously demonstrated that CD4
+CD25
+Tregs from cART-
treated chronically HIV-infected patients exerted a suppressive
activity on CD4 T-cell proliferative responses against CMV and
HIV-p24 [8]. Accordingly to recent published data [13,23], we
found that, even in patients with detectable viral load, the Tregs-
containing CD4
+ CD25
+ T-cell population from peripheral blood
retains a suppressive function on CMV and HIV-specific
proliferative responses.
Following cART interruption, the proportion of Tregs
increased as a consequence of T-cell activation driven by HIV
replication; anti-HIV specific CD8 T-cell responses enhanced and
broadened. Previous reports had suggested a role for the intensity
and the breadth of memory Gag-specific CTL on viral control
[43]. We found that HIV-DNA levels at M12 negatively correlated
with anti-gag but not total anti-HIV CD8 T-cell responses at M12.
A lack of correlation between the increase in HIV-specific CD8
+ T
lymphocyte frequencies and the viral set point after TI has already
been observed [31]. The polyfunctional profile of virus-specific
CD8 T-cells seems to be a better correlate of the virologic outcome
in patients who had interrupted cART [44].
We sought for factors at baseline which may independently
predict the CD4 T-cell drop and the increase in viral load following
TI and found no impact of Tregs on the immunovirologic outcome
at 12 months of TI. It is commonly accepted that persistent
immune activation plays a central role in driving CD4 T-cell
depletion [1,45,46].Our results indicate that the level of HIV-DNA
in PBMCs reflecting, at least in part, the size of the HIV reservoir
and the number of CD4
+ T cells, preferential targets of the virus,
were independent predictorsof CD4T-cell decline.We did notfind
any independent relationship between CD4 T-cell decline and the
level of CD4 and CD8 T-cell activation at least at baseline. In
contrast, we found that the increase in HIV-DNA levels in PBMCs
between baseline and M12 was independently predicted by the
number of CD4
+ T cells and the level of generalized T-cell
activation at baseline. The latter finding suggests that T-cell
activation may directly impact the HIV reservoir.
Figure 3. The increase in the proportion of Tregs between
baseline and M12 is independently related to the extent of
generalized T-cell activation following treatment interruption.
Relationship between the change in the percentages of CD8+ T cells co-
expressing HLA-DR and CD38 (x-axis) and the changes in the proportion
of CD25+ CD1272/low Tregs among CD4+ T cells (y-axis) between
baseline (prior to TI) and M12 of TI. Spearman’s correlation coefficient
R=0.433; p=0.031.
doi:10.1371/journal.pone.0011659.g003
Figure 4. Predictors of the immunovirologic outcome at month
12 of treatment interruption. Baseline HIV-DNA levels predict the
CD4 T-cell decline between baseline and M12 of TI. Relationship
between the levels of HIV-DNA in PBMCs at baseline prior to TI (x-axis)
and the change in CD4 cell counts between baseline and M12 of TI (y-
axis). Spearman’s correlation coefficient R=20.578; p=0.002.
doi:10.1371/journal.pone.0011659.g004
Figure 5. The proportion of CD8+ T cells co-expressing HLA-DR
and CD38 at baseline predicts the increase in HIV-DNA levels
between baseline and M12 of TI. Relationship between the
percentages of CD8+ T cells co-expressing HLA-DR and CD38 at
baseline prior to TI (x-axis) and the change in HIV-DNA levels in PBMCs
between baseline and M12 of TI (y-axis). The line corresponds to the
polynomial regression line (order 2), the overall non parametric
Spearman’s correlation coefficient R is estimated as 0.552; p=0.004,
while it is 0.440 (p=0.0357) after removing the two most extreme
values.
doi:10.1371/journal.pone.0011659.g005
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strongest independent predictor of the level of plasma HIV-RNA
achieved at M12. In the main trial, we found that HIV-DNA level
at treatment interruption, in addition to CD4 nadir and prior
AIDS event, was the only significant risk factors of reaching
criteria to resume cART [47].
In summary, our data indicate that in patients interrupting
cART, the level of HIV-DNA in PBMCs before TI independently
predicts the extent of CD4 T-cell decline and of viral control
achieved at M12, the latter being also predicted by the degree of
generalized immune activation before TI. Tregs seem to be
efficient in controlling residual immune activation in patients with
viral suppression under cART. However following TI, even if
Treg cells maintained a suppressive function, the inadequate
increase in the proportion of Tregs and/or the decrease in the
absolute number of Tregs resulted in a failure to control immune
activation. Further studies are needed to better define the impact
of different types of regulatory T cells on the natural history of
HIV infection from the primary infection.
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